TASS. The vaccine will be manufactured on the industrial site of the Vector research center.The Vector Research Center obtained the Russian Health Ministry’s permit to conduct clinical trials of its vaccine on volunteers in July.
The first volunteer was injected with the vaccine on July 27. The final group of 20 volunteers was discharged from the medical facility on September 8, according to TASS report."The clinical trials have been very successful.
The volunteers are developing the necessary titers and no one has any clinical signs after the vaccine - neither temperature nor any other reaction," Russia’s chief sanitary doctor Anna Popova said.